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Sorafenib tosylate inhibits directly necrosome
complex formation and protects in mouse models
of inflammation and tissue injury
Sofie Martens1,2, Manhyung Jeong3, Wulf Tonnus4, Friederike Feldmann5, Sam Hofmans6, Vera Goossens1,2, Nozomi Takahashi1,2,
Jan Hinrich Bräsen7, Eun-Woo Lee8, Pieter Van der Veken6, Jurgen Joossens6, Koen Augustyns6, Simone Fulda5,9,10,
Andreas Linkermann4, Jaewhan Song3 and Peter Vandenabeele*,1,2
Necroptosis contributes to the pathophysiology of several inflammatory, infectious and degenerative disorders. TNF-induced
necroptosis involves activation of the receptor-interacting protein kinases 1 and 3 (RIPK1/3) in a necrosome complex, eventually
leading to the phosphorylation and relocation of mixed lineage kinase domain like protein (MLKL). Using a high-content screening
of small compounds and FDA-approved drug libraries, we identified the anti-cancer drug Sorafenib tosylate as a potent inhibitor of
TNF-dependent necroptosis. Interestingly, Sorafenib has a dual activity spectrum depending on its concentration. In murine and
human cell lines it induces cell death, while at lower concentrations it inhibits necroptosis, without affecting NF-κB activation. Pull
down experiments with biotinylated Sorafenib show that it binds independently RIPK1, RIPK3 and MLKL. Moreover, it inhibits
RIPK1 and RIPK3 kinase activity. In vivo Sorafenib protects against TNF-induced systemic inflammatory response syndrome
(SIRS) and renal ischemia–reperfusion injury (IRI). Altogether, we show that Sorafenib can, next to the reported Braf/Mek/Erk and
VEGFR pathways, also target the necroptotic pathway and that it can protect in an acute inflammatory RIPK1/3-mediated
pathology.
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A delicate balance between cell death and proliferation is
essential for tissue homeostasis in multicellular organisms.1,2
Disturbance of this balance underlies the pathogenesis of
various diseases, such as inflammatory and degenerative
diseases, infectious diseases and cancer.3 Necrotic cell death
is characterized by swelling and bursting of the cell, thereby
releasing cytokines, chemokines and damage-associated
molecular pattern molecules (DAMPs), which in a concerted
way propagate inflammation.4 The discovery of necroptosis as
a programmed form of necrosis that is regulated by the
signaling of receptor-interacting protein kinases 1 and 3
(RIPK1/3),5–9 allowed to envisage necroptosis as a druggable
process. Necroptosis can be triggered by DNA damage,
immune receptors, viruses or death receptors of the TNF
superfamily, such as Fas receptor (FasR), TRAILR1/2 or death
receptor 3 (DR3),2,4 but the best characterized is TNFR1-
induced necroptotic signaling. Upon stimulation with TNF, TNF
receptor 1 (TNFR1) trimerizes10 and a membrane-associated
protein complex (TNFR1 complex I) is formed.11 Ubiquitylation
of RIPK1 in this survival signaling complex results in activa-
tion of the IκB kinase (IKK)-complex,12 which causes
degradation of IκB-α and thus NF-κB activation. When
inhibitors of apoptosis (IAPs), TGFβ activated kinase-1
(TAK1) or inhibitor κB kinases (IKKs) are blocked, RIPK1
kinase is activated and results in RIPK1-dependent apoptosis
or necroptosis.13 When caspase-8 is inhibited14–16 or FADD is
absent,17 the necrosome complex consisting of RIPK1 and
RIPK3 is formed. Activated RIPK3 phosphorylates mixed
lineage kinase domain like protein (MLKL), which relocates to
the plasma membrane and directly18,19 or indirectly20,21
affects plasma membrane permeabilization. Necrostatins
were the first identified inhibitors of necroptosis targeting
RIPK1,5,22 but no necrostatin-like drugs have been reported to
have reached preclinical development. We identified the FDA-
approved Sorafenib tosylate (further referred to as Sorafenib)
as a potent inhibitor of necroptosis in two independent
screening assays using L929 cells. Sorafenib is a multi-
kinase inhibitor that induces apoptosis of cancer cells23–25 and
is clinically used to treat advanced hepatocellular carcinoma
(HCC), advanced renal cell carcinoma,26 and acute myeloid
leukemia (AML).27 Sorafenib exerts anti-tumor effects by
inhibiting kinases involved in cell proliferation and survival. It
inhibits tumor cell proliferation26,28 and angiogenesis26
through inhibition of Raf1 kinase29 and VEGFR1/2/3,
PDGFRb, FGFR1 receptor tyrosine kinases29 respectively.
Other cellular processes that are affected by Sorafenib are
1VIB-UGent Center for Inflammation Research (IRC), Ghent, Belgium; 2Department of Biomedical Molecular Biology (DBMB), Ghent University, Ghent, Belgium;
3Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Korea; 4Department of Internal Medicine III, Division of Nephrology,
University Hospital Carl Gustav Carus at Technische Universität Dresden, Dresden, Germany; 5Institute for Experimental Cancer Research in Pediatrics, Goethe-University,
Frankfurt, Germany; 6Laboratory of Medicinal Chemistry, University of Antwerp, Antwerp, Belgium; 7Department of Pathology, Hannover Medical School, Hannover,
Germany; 8Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, South Korea; 9German Cancer Research
Center (DKFZ), Heidelberg, Germany and 10German Cancer Consortium (DKTK), Partner Site Frankfurt, Germany
*Corresponding author: V Peter , Department of Biomedical Molecular Biology, VIB, Ghent University, Technologiepark 927, Gent-Zwijnaarde, Ghent 9052, Belgium.
Tel: +32 93 313720; Fax: +32 93 313609; E-mail: Peter.Vandenabeele@irc.vib-ugent.be
Received 10.5.17; Received 23.5.17; accepted 25.5.17; Edited by G Raschellà
Citation: Cell Death and Disease (2017) 8, e2904; doi:10.1038/cddis.2017.298
Ofﬁcial journal of the Cell Death Differentiation Association
www.nature.com/cddis
ER-stress mediated cell death independent of MEK and
ERK30 and mTOR-mediated autophagy in HCC.31 It seems
paradoxical that Sorafenib, a potent cytostatic and cytotoxic
drug, inhibits necroptosis. We demonstrate that Sorafenib
exerts this dual activity depending on its concentration.
Furthermore, we show the inhibition of RIPK1 and RIPK3 as
the mechanism underlying this novel function of Sorafenib.
Results
Compound screenings in cellular models of TNF-
mediated necroptosis identify Sorafenib as a potent
necroptosis inhibitor. To identify novel inhibitors or regula-
tors of necroptosis, 500 small compounds from libraries
targeting autophagy, kinases, phosphatases, proteases and
redox balance were screened for their ability to block
TNF-induced necroptosis in murine L929sAhFas cells. Three
conditions were used to induce necroptosis in L929 cells:
TNF alone, TNF+TAK1 inhibitor (TAK1i) and TNF+zVAD-fmk,
a pan-caspase inhibitor. Inhibition of TAK1 or caspases
sensitizes to necroptosis.13,32 Necroptosis, measured as the
percentage of PI-positive nuclei normalized to the plate-
specific DMSO control, was determined for each compound
(Supplementary Figure 1A). Z’ values for the TNF- and TNF
+TAK1i-induced cell death assay were 0.498 and 0.919,
respectively (Supplementary Figures 2A and B), indicating
good assay performance. Sorafenib was identified as an
effective inhibitor of both TNF- and TNF+TAK1i-induced
necroptosis (Figure 1a). Sorafenib reduced TNF-induced
cell death to 40% of control, and it almost completely
blocked TNF+TAK1i-induced cell death. In an independent
screening with 437 FDA-approved drugs and TNF+zVAD-fmk
as necroptosis trigger in L929 cells (Supplementary
Figure 1B), Sorafenib was also shown to be a potent inhibitor
(Figure 1b). Under sensitizing conditions (TAK1i or zVAD-
fmk), Sorafenib (10 μM) was equally potent as necrostatin-1
(10 μM) and the recently reported RIPK1 inhibitor pazopanib,
a multi-target inhibitor of VEGFR1/2/3, PDGFR, FGFR, c-KIT
and c-Fms.33 Other kinase inhibitors from the screening with
similar targeting profiles as Sorafenib did not protect against
necroptosis (Supplementary Tables 1–3), suggesting that
necroptosis inhibition by Sorafenib is not due to inhibition of
its known targets (Raf1 kinase, VEGFR1/2/3, PDGFRb,
FGFR1 receptor tyrosine kinases).29
Sorafenib protects against TNF-induced cell death at
non-toxic concentrations. Since Sorafenib induces apop-
tosis and cytostasis,29,33 we determined dose-responses in
the presence or absence of necroptosis stimulus. As a
chemotherapeutic drug Sorafenib induces cell death in a
dose- and time-dependent manner at concentrations above
25 μM, reaching close to 100% cell death after 48 h at 100 μM
in L929sAhFas cells (EC50 is 39.6 μM) (Figure 1c, left panel;
Supplementary Figure 3). A dose-dependent cytostatic effect
of Sorafenib was observed 10 days after removal of stimulus
in a clonogenic assay (Figure 1d). However, in the same
L929sAhFas cells, Sorafenib inhibited necroptosis induced
by TNF alone or in sensitized condition (TNF+TAK1i) at
concentrations below 10 μM without inducing cell death
(Figure 1c, right panel). Altogether, these data demonstrate
that Sorafenib is cytotoxic at high concentration on its own,
while it protects against TNF-induced necroptosis at more
than 10-fold lower concentration (Figure 1c; Supplementary
Table 4).
Sorafenib inhibits TNF-induced RIPK1-dependent cell
death in murine and human cell lines. To confirm the
inhibition of TNF-induced necroptosis by Sorafenib, we tested
a panel of murine (L929sAhFas and MEF) and human cell
lines (HT-29, Jurkat FADD-/-, and two AML cell lines MV4-11
and Molm13). Smac mimetic BV634 instead of TAK1i was
used as a sensitizer for testing of mouse embryonic fibro-
blasts (MEF) and human cell lines. Dose-response curves
and IC50 values for the potency of Sorafenib to inhibit cell
death, were determined and compared with Nec-1s, as a
reference compound.22 As for murine cells, L929sAhFas and
MEF cells stimulated with mTNF or with mTNF/smac mimetic
BV6/zVAD-fmk (Figures 2a and b), Sorafenib inhibited
necroptosis with an IC50 value of 1.27 μM and 3.48 μM
respectively, as compared with 0.24 μM and 0.63 μM for Nec-
1s (Figures 2a and b; Supplementary Table 4). To investigate
whether the protective effect of Sorafenib at o10 μM is
specific for necroptosis, we tested apoptotic conditions in
both L929sAhFas and MEF cells. Pretreatment with Sorafe-
nib did not protect L929sAhFas cells from apoptosis induced
by agonistic anti-Fas antibody (AF). However, Sorafenib did
protect against RIPK1-dependent apoptosis in MEF cells
induced by mTNF/BV6 (IC50 of 2.20 μM) (Supplementary
Figure 4B). This demonstrates that Sorafenib inhibits
RIPK1-dependent apoptosis and necroptosis equally, but
not RIPK1-independent apoptosis. As for human cell lines,
Sorafenib protected against necroptotic stimuli in HT-29 cells
(Figure 2c) as well as Jurkat FADD-/- cells (Figure 2d). Since
Sorafenib is used to treat AML,27 we also included two AML
cell lines to investigate whether it alters the sensitivity of
these cells to necroptotic stimuli (BV6 in the presence of
zVAD-fmk).34 Sorafenib significantly reduced BV6/zVAD-fmk-
induced necroptosis of AML cells in a dose-dependent
manner (Figures 2e and f). Similar to the L929sAhFas
cell line (Figure 1c), the human AML cells underwent
Sorafenib-induced cell death (EC50 of 19.6 μM for MV4-11
cells) (Supplementary Figures 4C and D), while they were
protected against BV6+zVAD (IC50 Molm13 of⩽ 0.03 μM)
(Figures 2e and f). Addition of Nec-1s significantly decreased
BV6/zVAD-fmk-mediated necroptosis of AML cells (Figures
2e and f). In all human cell lines tested Sorafenib protected
against necroptosis stimuli (Figures 2c–f) but with variable
IC50 values (Supplementary Table 4). Overall, we confirm
that Sorafenib at o10 μM protects against TNF-induced
RIPK1-dependent cell death, with a three-fold higher effi-
ciency in murine cell lines than in human cell lines.
Sorafenib does not influence the TNF-induced NF-κB
activation, but protects against necroptosis by targeting
the necrosome complex. We questioned whether NF-κB
mediated survival signaling was involved in the protection by
Sorafenib. Similar to Nec-1s, Sorafenib pretreatment did not
prevent the phosphorylation and degradation of IκB-α, the
inhibitor of NF-κB,35 after TNF stimulation of L929 or
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L929sAhFas cells (Figure 3a; Supplementary Figure 5). We
also examined relative mRNA levels of NF-κB responsive
genes, including A20 and IκB-α.36 TNF stimulation of L929
cells (Figures 3b and c) and L929sAhFas cells (Supple-
mentary Figure 6) resulted in a ten-fold induction of A20 and
IκB-α mRNA, and the presence of Sorafenib did not affect this
gene induction. Thus NF-κB activation after TNF stimulation
and subsequent survival signaling is not impaired by
Sorafenib. Moreover, Sorafenib did not affect the RIPK1,
RIPK3 and MLKL protein levels (Figure 3a), excluding their
transcriptional control as a mechanism of Sorafenib-mediated
inhibition of necroptosis. Although A20 and IκB-α gene
induction was not affected, induction of cytokines and
chemokines (TNF-α, MIP-2, MCP1 and CXCL1) was strongly
reduced by Sorafenib (Supplementary Figure 6), suggesting
that other kinases involved in transcriptional regulation are
affected by Sorafenib. The above results suggested that
the formation of complex I and RIPK1 polyubiquitylation,
absolute requirements for NF-κB signaling, are not impaired
by Sorafenib. Indeed, immunoprecipitation of TNFRI after
Figure 1 Compound screenings in cell models of TNF-mediated necroptosis identify Sorafenib as a potent necroptosis inhibitor, when used at non-cytotoxic concentrations.
After compound treatment, L929sAhFas (a) or L929 (b) cells were stimulated with mTNF (T), mTNF+Tak1i (TiT) or mTNF+zVAD (zVT) (Supplementary Figure 1A and B). (a) Cell
death percentage (% PI-positive nuclei) or cell loss was calculated as percent of control (DMSO+stimulus). Green points marked by the green dotted line represent a selection of
kinase inhibitors from the screening on L929sAhFas cells (Supplementary Table 1), that are only slightly protective in the TNF-stimulated condition. (b) Cell loss (luminescence-
based readout for ATP) was calculated as percent of control (DMSO+stimulus). (c) L929sAhFas cells were pretreated with DMSO, Nec-1s or Sorafenib (concentrations as
indicated) for 19 h (mTNF+Tak1i) or 1 h (mTNF), followed by stimulation with 3.8 ng/ml mTNF+1 μM Tak1i (mTTi) for 3 h, 0.2 ng/ml mTNF for 24 h or left unstimulated to
determine cytotoxicity of the compound itself. In stimulated conditions, % PI-positive nuclei was determined as % of DMSO control. Data represent mean values± S.E.M. of two
independent experiments. Cells were stained with Hoechst and PI and percentage PI-positive nuclei was determined using high-content image analysis (BD pathway Bioimager).
(d) L929sAhFas cells were treated with Sorafenib (concentration as indicated) for 24 h. Then, stimulus was removed, 50 cells/condition seeded and colonies counted with crystal
violet staining after 10 days incubation. Quantification was performed using ImageJ. n= 2, a representative experiment is shown
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mTNFα stimulation showed similar patterns of RIPK1 poly-
ubiquitylation in both DMSO- and Sorafenib-pretreated L929
cells (Figure 3d). Immunoprecipitation of FLAG-hTNF after
5 min of stimulation of L929sAhFas cells resulted in
polyubiquitylation of RIPK1, which was not altered by
Nec-1s or Sorafenib treatment (Supplementary Figure 7).
Next, we investigated whether necrosome formation, invol-
ving activation and autophosphorylation of both RIPK1 and
RIPK3,5–8 was affected by pretreatment with Sorafenib. The
recruitment of both RIPK1 and RIPK3 to FADD after 3–4 h of
TNF/zVAD-fmk stimulation of L929 cells was markedly
reduced in Sorafenib-treated L929 cells (Figure 3e). Sorafe-
nib not only inhibited necrosome formation in murine L929
cells, but also in human HT-29 cells (Figure 3f). Collectively,
these data show that Sorafenib inhibits neither TNF complex I
formation nor NF-κB signaling, but interferes with necrosome
formation preventing necroptosis to occur.
Identification of RIPK1 and RIPK3 as targets of Sorafenib.
Since Sorafenib is a broad-spectrum tyrosine kinase
inhibitor,26 it may target both RIP kinases and other kinases
important for TNF cytotoxic signaling. Prevention of necro-
some formation by Sorafenib implies that Sorafenib may
interact with RIPK1 and/or RIPK3. To identify targets of
Sorafenib during TNF signaling, biotinylated Sorafenib was
synthesized (Figure 4a). Several Sorafenib variants were
synthesized containing different substituents in the R-position
(Supplementary Figure 8), to test whether biotinylation of
Figure 2 Sorafenib inhibits TNF-induced RIPK1-dependent cell death in both murine and human cell lines and rescues AML cells from Smac mimetic-induced necroptosis.
(a,b) L929sAhFas and MEF cells were pretreated for 1 h with DMSO, Nec-1s or Sorafenib (concentration as indicated) and stimulated for 4.25 h (L929) or 3 h (MEF) with 38 ng/
ml mTNF, 1 μM BV6 and 10 μM zVAD, as indicated. (c,d) HT-29 and Jurkat FADD− /− cells were pretreated for 1 h with DMSO, Nec-1 or Sorafenib (concentrations as
indicated) and stimulated for 6 h with 30 ng/ml hTNF, 1 μM BV6 and 30 μM zVAD (HT-29) or stimulated for 10 h with 100 ng/ml hTNF (Jurkat FADD− /− ). (a-d) Data were
normalized to DMSO-treated control cells and represent the mean value± S.E.M. of three independent experiments. Toxic concentrations were removed from the analysis.
L929sAhFas and MEF cells were stained with Hoechst and PI and percentage PI-positive nuclei was determined using high-content image analysis (BD pathway Bioimager). For
HT-29 and Jurkat FADD− /− cells, cell death was determined by PI staining and flow cytometry. (e,f) MV4-11 and Molm13 cells were pretreated for 1h with 40 μM zVAD-fmk and
Sorafenib or Nec-1s (concentration as indicated) and stimulated for 6h (Molm13) or 24h (MV4-11) with 3 μM BV6. Cell death in AML cells was determined by PI staining and flow
cytometry. Mean and S.D. of three independent experiments performed in triplicate are shown
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Sorafenib was possible without losing its inhibitory potency.
The biotinylated analog of Sorafenib showed a lower
inhibitory potency and thus had to be used at higher
concentrations for similar efficacy (Supplementary Figure 8,
compound 10). To identify binding partners of biotinylated
Sorafenib, a pull down of biotinylated Sorafenib in unstimu-
lated cell lysates of L929sAhFas was performed. We show
a dose-dependent pull down of RIPK1, RIPK3, MLKL and
B-Raf (Figure 4b; Supplementary Figure 9). Other kinases,
like ERK1/2, p38MAPK and HPK1, were not detected in the
Figure 3 Sorafenib does not influence complex I formation, but protects against necroptosis by targeting the necrosome complex. (a) L929 cells were pretreated with 10 μM
Nec-1s, Sorafenib or DMSO for 1 h and stimulated with mTNF (10 ng/ml) for the indicated time. Cells were lysed and immunoblotted with the indicated antibodies.
*Phosphorylated RIPK1. (b,c) L929 cells were pretreated with 10 μM DMSO, Nec-1 or Sorafenib for 1 h and stimulated with mTNF (10 ng/ml) for 2 h. The relative mRNA levels of
mA20 and mIκB-α were analyzed by qRT-PCR. All bars represent mean±S.D.; n= 3, ns= non-significant. (d) L929 cells were pretreated with 10 μM Sorafenib or DMSO and
stimulated with mTNF (10 ng/ml) for the indicated time. Cell lysates were immunoprecipitated with anti-mTNFR1 antibody. (e,f) L929 (e) and HT-29 (f) cells were pretreated with
10 μM Nec-1, Sorafenib (Sora) or DMSO and stimulated with zVAD (10 μM)+mTNF (5 ng/ml) (L929) or zVAD (30 μM)+BV6 (1 μM)+hTNF (30 ng/ml) (HT-29) for the time
indicated. Cell lysates were immunoprecipitated with the indicated antibodies and both immunoprecipitates (IP) and total lysates (input) were immunoblotted with the indicated
antibodies (WB)
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pull down, demonstrating the specificity of the binding.
Detection of Hsp90 in the pull down is not suprising, as
Hsp90 is known to act as a chaperone for RIPK1 stabiliza-
tion,37 RIPK3 activation38 and MLKL oligomerization39 during
necroptosis execution (Figure 4b). These data suggested that
Sorafenib binds either to a (pre-formed) multi-protein complex
Sorafenib inhibits necrosome formation
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containing RIPK1, RIPK3 and MLKL or to all three proteins
independently. Interestingly, we were able to pull down each
of the three necrosome components (RIPK1, RIPK3, MLKL)
in MEF cell lysates from the following mice strains: RIPK1+/+,
RIPK1− /− , RIPK3+/+, RIPK3− /− , MLKL+/+ and MLKL− /− .
This experiment demonstrates that Sorafenib is likely to
bind independently to RIPK1, RIPK3 or MLKL (Figure 4c),
even in the absence of a necroptotic stimulus. Together with
the data of the immunoprecipitation of TNFR1 (complex I)
and FADD (complex II) after TNF stimulation, we conclude
that Sorafenib can bind RIPK1, RIPK3 and MLKL and hereby
prevents the formation of the necrosome.
In order to test whether Sorafenib directly inhibits kinase
activities of RIPK1 or RIPK3, different in vitro kinase assays
were performed (Figures 4d and e). A non-radioactive in vitro
ATPγS kinase assay was performed with recombinant GST-
hRIPK1.40 Incubation of recombinant GST-hRIPK1 with Nec-
1s or Sorafenib resulted in a strong decrease in RIPK1
autophosphorylation compared with the DMSO control,
although Sorafenib was less efficient than Nec-1s
(Figure 4d, upper figure). IC50 values of Sorafenib and Nec-
1s were 1.5 μM and 1 μM respectively in an in vitro ADP-Glo
kinase assay41 using recombinant hRIPK1 (Figure 4d, lower
figure), confirming the results of the in vitro ATPγS kinase
assay. Finally, 50 μM Sorafenib inhibited mRIPK3 autopho-
sphorylation in a radioactive kinase assay with FLAG-mRIPK3
(Figure 4e). Although Sorafenib can bind to MLKL in cell
lysate, it does not protect against ligand independent MLKL-
induced cell death (Supplementary Figure 10), excluding
functional targeting on MLKL. Altogether, these data illustrate
that Sorafenib can bind to RIPK1 and RIPK3 and inhibit their
kinase activities.
Sorafenib protects against TNF-induced systemic inflam-
matory response syndrome and renal ischemia–reperfu-
sion injury. To examine whether Sorafenib could protect
against RIPK kinase-driven inflammation in vivo, we tested it
in the TNF-induced SIRS model. This is a sterile model of
sepsis that depends on RIPK1 kinase activity and RIPK3.42,43
Sorafenib, administered by gavage 1.5 h before i.v. mTNF
treatment, significantly protected mice from hypothermia and
death caused by mTNF in a dose-dependent manner
(Figures 5a and b). Mice pretreated with Nec-1s were fully
protected, while about 50% of mice pretreated with Sorafenib
survived (Figure 5a). The IL-6 concentration in plasma of
Sorafenib-treated mice (100 mg/kg), like Nec-1s-treated
mice, are significantly lower than vehicle-treated mice after
6 h TNF challenge (Figure 5d). On the other hand, TNF
concentration was not significantly lower under these
conditions (Figure 5e). In conclusion, these results indicate
that Sorafenib not only protects against RIPK1/3-dependent
cell death in vitro, but also against RIPK1/3-dependent
lethality in TNF-induced SIRS. As Nec-1 treatment and
RIPK3-deficiency are beneficial in the model of renal
ischemia–reperfusion injury,44,45 we investigated the effect
of Sorafenib in this model of tissue injury and inflammation as
well. Low-dose Sorafenib protected against histological
damage (Figures 5f and g) and functionally ameliorated
acute renal failure, as demonstrated by reduced serum
creatinine and urea 48 h after reperfusion (Figures 5h and i).
Higher dose of Sorafenib however sensitized the mice to
ischemic damage and led to deterioration of acute renal
failure (Supplementary Figure 11). We conclude that Sor-
afenib provided protection in two in vivo models of tissue
injury and inflammation driven by RIPK1/RIPK3-dependent
cell death.
Discussion
We performed cellular screenings with targeted small com-
pound libraries (for kinases, phosphatases, proteases, redox-
regulation, autophagy) and an FDA-approved drug library in
order to identify inhibitors of necroptosis. From the results, we
selected Sorafenib for further characterization as an inhibitor
of necroptosis, not only because it protected against different
necroptosis inducing stimuli but also because it is an FDA-
approved drug that is used in clinic to treat advanced
hepatocellular carcinoma,46 renal cell carcinoma47 and
AML.27 Several necroptosis inhibitors have been discovered
or designed to target RIPK1,5,48 RIPK349 and MLKL,50,51 the
core necroptosis pathway,52 but none of them are already in
clinical use.53 Sorafenib is not the only anti-cancer drug that
can inhibit necroptosis. Recently, Pazopanib, first proposed as
a multi-target inhibitor of VEGFR1/2/3, PDGFR, FGFR, c-KIT
and c-Fms and approved for the treatment of advanced renal
cell carcinoma, and Ponatinib, first described as Pan-Bcr-Abl
tyrosine kinase inhibitor and approved for the treatment of
chronic myeloid leukemia, were both reported as necroptosis
inhibitors at the submicromolar range,33 the former blocking
mainly RIPK1 and the second blocking both RIPK1 and
RIPK3. Ponatinib has been used as template to design new
inhibitors with improved selectivity for RIPK1.54 The
B-RafV600E inhibitors Vemurafenib and Dabrafenib inhibit
RIPK3, with Dabrafenib being effective in the submicromolar
range.55 Dabrafenib competes with ATP for binding to RIPK3
and alleviates acetaminophen-induced liver injury.55 Here, we
demonstrate that the anti-cancer agent Sorafenib acts as an
inducer of cell death at high concentration but as an inhibitor of
RIPK-dependent cell death at lower concentration.
Figure 4 Identification of RIPK1 and RIPK3 as targets of Sorafenib tosylate. (a) Structure of biotinylated Sorafenib tosylate. (b,c) Streptavidin pull down of biotinylated
Sorafenib. DMSO (D), biotin (b) or 10 μM/20 μM/50 μM/100 μM biotinylated Sorafenib (biot. Sor.) was added to L929sAhFas cell lysate and 50 μM biotinylated Sorafenib (S) to
MEF cell lysates, followed by pull down with streptavidin beads. Both pull down samples and total lysates (pre-PD) were analyzed by SDS-PAGE and immunoblotted with the
indicated antibodies. L929sAhFas whole cell lysate (WCL) was included as loading control. (d) In vitro non-radioactive ATPγS kinase assay (upper figure) and in vitro ADP-Glo
kinase assay (lower figure and table) using recombinant hRIPK1 protein (100 nM). Recombinant hRIPK1 was incubated with 50 μM Nec-1s, Sorafenib or DMSO (upper figure) or
with a concentration as indicated. (e) FLAG-mRIPK3 purified from 293FT cells was pre-incubated with indicated chemicals (conc. as indicated) for 15 min at 25 °C and incubated
with [γ-32P]ATP for in vitro radioactive kinase assay
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The kinase domain of B-rafV600E has strong structural
homology with the kinase domains of hRIPK1 and hRIPK3,
which explains the similarities between the crystal structure of
Nec-1 bound to RIPK1 and the structure of Vemurafenib
bound to B-RafV600E.56 The crystal structure of B-Raf bound to
Sorafenib indicates that Sorafenib occupies the ATP-binding
Figure 5 Sorafenib protects against TNF-induced systemic inflammatory response syndrome (SIRS) and renal ischemia–reperfusion injury (IRI). Survival curve (a) and body
temperature (b,c) (means± S.E.M.) of WT mice (n= 12) injected with mTNF (500 μg/kg i.v.) after pretreatment with Nec-1s (6.25 mg/kg i.v.) or Sorafenib (10/50/100 mg/kg
gavage). Control mice (n= 12) received an equal amount of vehicle before the mTNF challenge. Results of three independent experiments are shown. (d,e) Plasma samples of
Solvent-, Nec-1s- (6.25 mg/kg i.v.) and Sorafenib-treated mice (100 mg/kg gavage) (n= 6/group) were collected 0 h and 6 h after mTNF challenge (375 μg/kg i.v.) and analyzed
for mTNF-α and mIL-6. (c–e) A one-way ANOVA test with Bonferroni multiple-testing correction was performed. *Po0.05, **Po0.01, and ****Po0.0001 versus control mice.
(f–i) Histology, tubular damage score and serum urea/creatinine levels of mice treated with vehicle or Sorafenib (10 mg/kg i.p.) 15 min before initiation of ischemia. Mice were
killed 48 h after reperfusion and kidneys were removed after retro-orbital blood puncture. Stained kidney sections were analyzed using an Axio Imager microscope (Zeiss). Organ
damage was quantified by an experienced pathologist in a double-blind manner on a scale ranging from 0 (unaffected tissue) to 10 (severe organ damage), *Po0.05 and
**Po0.01
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pocket and keeps the protein in an inactive conformation.57 As
the broad-spectrum tyrosine kinase inhibitor Sorafenib was
originally designed as a Raf1-inhibitor,26 and given the
homology between B-RafV600E and the kinase domain of
hRIPK1/3,56 we speculated that Sorafenib could also bind
RIPK1/3 by targeting the kinase domain. The protection of
Sorafenib against TNF-induced necroptosis cannot be
explained by inhibition of its known targets (Raf B/C kinase,
VEGFR1/2/3, PDGFR, c-KIT, RET, Flt3),58 since small
compounds with similar target profiles, like Vandetanib
targeting VEGFR-2/KIT/PDGFR, do not protect from necrop-
totic cell death.33 Also, compounds like GW5074, SU1498,
Tyrphostin AG1295 and PP1, targeting Raf kinase, VEGFR,
PDGFR and Src kinase respectively do not inhibit necroptosis
(Supplementary Tables 1–3). Moreover, we show that
Sorafenib can bind either a complex containing RIPK1, RIPK3
and MLKL or to each of these proteins separately. Finally, we
showed that Sorafenib protected against two models of RIPK-
driven inflammation and tissue injury, namely TNF-induced
SIRS, a sterile model for sepsis,42 and renal ischemia–
reperfusion injury (IRI).59 It has been shown that Sorafenib can
be used efficiently to block Hepatitis C virus replication and
viral gene expression60 and Rift Valley fever virus infection.61 It
is also reported that Sorafenib can protect against ischemia/
reperfusion (IR) injury in rats with nonalcoholic steato-
hepatitis,62 is able to reverse LPS-induced hypotension by
targeting soluble epoxide hydrolase (sEH), an enzyme with
pleiotropic effects on inflammation and vascular disease,63
and is also able to restore workingmemory abilities in amouse
model for Alzheimer’s disease (AD) by inhibition of the pro-
neuroinflammatory factor cRaf-1 and NF-κB.64 Thus Sorafenib
exerts an anti-inflammatory activity in other in vivo experi-
mental diseases models. Given the inflammatory response
triggered by release of cytokines, chemokines and DAMPs
from necroptotic dying cells,42,59 these reported anti-
inflammatory effects of Sorafenib in vivo may be attributed to
its potent necroptosis targeting effect we describe here. In
HCC, chronic inflammation is known to promote tumor
progression and metastasis, with a pivotal role for TNF in
promoting invasion, angiogenesis and metastasis.65,66 As
necroptosis throughDR6 in tumor-associated endothelial cells
has been described as a metastasis promoting process,67 the
efficacy of Sorafenib in HCC could, besides the direct
cytotoxicity on tumor cells, be due to necroptosis inhibition
preventing pro-inflammatory DAMP release in the necrotic
core and so reducing the inflammation-dependent tumor
growth68 and preventing endothelial necroptosis and
metastasis.67 As Sorafenib is not specifically inhibiting
necroptosis but also RIPK1 kinase dependent apoptosis,
one could envisage that during experimental disease models
in vivo it may target simultaneously RIPK1-dependent
necroptosis and apoptosis. Recent evidence illustrates that
TNF-induced SIRS is a consequence of both caspase-8-
dependent apoptosis and MLKL-dependent necroptosis.43
Sorafenib inhibits both RIPK1-dependent apoptosis and
necroptosis, which may explain its protective effect during
TNF-induced SIRS model.
Repurposing FDA-approved drugs is a new and valuable
strategy to offer new therapies for diseases that remain difficult
to treat69,70 such as sepsis, degenerative disorders and
metabolic diseases. However, more extensive in vivo experi-
ments need to be performed to explore possible repurposing
of Sorafenib to treat these human disease conditions. Our data
also indicate that Sorafenib at low concentrations can interfere
with therapeutic induction of necroptotic cell death in AML
cells. Since some targeted therapies such as Smac mimetic in
combination with epigenetic drugs have been shown to trigger
necroptosis as an alternative mode of cell death in apoptosis-
resistant AML cells,71,72 these findings imply that Sorafenib
may limit the anti-leukemic activity under certain conditions. To
conclude, we identified the necroptotic pathway as a novel
Sorafenib-targeted pathway through inhibition of the necro-
some formation. We also demonstrated that Sorafenib
alleviated inflammation and tissue injury in two experimental
disease models in mice which are driven by RIPK-dependent
cell death, suggesting that necroptosis targeting could be part
of the therapeutic potential of Sorafenib.
Materials and Methods
Cell culture, cytokines and reagents. L929 cells were purchased from
ATCC (used in Korean Lab), L929 cells stably transfected with hFas and designated
as L929sAhFas (used in Belgian Lab) were generated as previously described.14
All L929 cell lines and MEF cells were cultured in DMEM supplemented with
10% (v/v) FCS and L-glutamine (0.03%). Jurkat FADD− /− cells were cultured in
RPMI medium supplemented with 15% (v/v) FCS, sodium pyruvate (400 μM) and
L-glutamine (0.03%). HT-29 cells were cultured in McCoy’s 5A medium
supplemented with 10% (v/v) FBS. AML cell lines were obtained from DSMZ
(Braunschweig, Germany) and were cultured in RPMI 1640 medium (Life
Technologies, Eggenstein, Germany), supplemented with 10% FCS (Biochrom,
Berlin, Germany), 1 mM Pyruvate (Invitrogen, Karlsruhe, Germany) and 1%
penicillin/streptomycin (Invitrogen). Following cytokines and reagents were used:
recombinant (rec) human and murine TNF were produced at VIB protein Service
Facility (Ghent, Belgium) with a specific biological activity of 3 × 107 IU/ml and
1.27 × 108 IU/ml (batch 2: 4.93 × 107 IU/ml) respectively, human and murine rec TNF
were also purchased from Sigma-Aldrich (T0157) and eBioscience (14-8321-62)
respectively (Korean Lab), rec FLAG-hTNF was produced at VIB Protein Service
Facility (Ghent, Belgium) and was used at 1.5 μg/ml. Following reagents were
purchased as indicated: necrostatin-1 (Calbiochem, San Diego, CA, USA and Enzo
life science, Farmingdale, NY, USA), necrostatin-1s (synthesized by the laboratory
of Medicinal Chemistry; University of Antwerp), Sorafenib tosylate (Selleck
Chemicals, Houston, TX, USA), SMAC mimetic BV6 (Selleck Chemicals), Tak1
kinase inhibitor NP-009245 (AnalytiCon Discovery GmbH, Potsdam, Germany),
zVAD-fmk (Bachem, Bubendorf, Switzerland and R&D systems) and agonistic anti-
human Fas (clone 2R2, Cell Diagnostica, Munster, Germany). Libraries used are:
autophagy library (BML-2837), epigenetics library (BML-2836), kinase inhibitor
library (BML-2832), phosphatase inhibitor library (BML-2834), protease inhibitor
library (BML-2833), redox library (BML-2835) (Screen-well, Enzo Life Sciences) and
437 FDA-approved drug library (SelleckChem, L1300).
Antibodies. Antibodies used were anti-RIPK1 (BD Biosciences, San Jose, CA,
USA, #610459), anti-actin (MP Biomedicals, Solon, OH, USA, #69100), anti-IκB-α
(Santa Cruz Biotechnology, Dallas, TX, USA, #sc-371), anti-hRIPK3 (ThermoFisher
Scientific Pierce, Waltham, MA, USA, PA1-41533), anti-mRIPK3 (Sigma-Aldrich, St
Louis, MO, USA, #R4277 and IMGENEX, San Diego, CA, USA,, IMG-5523-2), anti-
hMLKL (Genetex, Irvine, CA, USA, GTX107538), anti-mMLKL (Millipore, Billerica,
MA, USA, #MABC604 and Abgent, San Diego, CA, USA, AP14272b-ev), anti-
phospho-hMLKL (Abcam, Milton, Cambridge, UK, #187091), anti-hFADD (BD
Biosciences, 610399), anti-mFADD (Millipore, 05-486), anti-thiophosphate ester
(Epitomics, Burlingame, CA, USA, #2686-1), anti-Braf (ThermoFisher scientific,
MA5-15495), anti-HPK1 (Cell Signaling, Danvers, MA, USA, #4472), anti-Hsp90
(Santa Cruz Biotechnology, sc-7947), anti-p38MAPK (Cell Signaling, #9212), anti-
ERK1/2 (Cell Signaling, #9102), anti-Flag-HRP (Sigma-Aldrich, St Louis, MO, USA,
#A8592) and anti-tubulin-HRP (Abcam, #ab21058). Secondary antibodies used
were HRP-conjugated secondary antibodies against mouse, rabbit or rat
immunoglobulin (GE Healthcare, Little Chalfont, Amersham, UK).
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Immunoprecipitation. For TNFRI complex I and necrosome IP, DISC buffer
composed of 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% Triton
X-100, protease inhibitors and 10% glycerol were used to lyse pretreated L929 or
HT-29 cells. After the lysis step, each complex was purified by IP using 1 μg of
α-mTNFR1 (R&D systems, AF-425-PB) for TNFRI complex I, 1 μg of α-mFADD
(Santa cruz, sc-6036) for mouse necrosome or 1 μg of α-hRIPK3 (ThermoFisher
Scientific Pierce, PA1-41533) at 4 °C. In order to pull down each antibody-bound
complex, protein G agarose beads (GE Healthcare, 17-0618-01) were incubated
with cell lysates for 2 h, followed by 3x washing with DISC buffer. The
immunoprecipitated complexes were eluted in boiled condition and analyzed by
immunoblotting (antibodies used as indicated). Pull down of biotinylated Sorafenib
was performed by adding DMSO, biotin or biotinylated Sorafenib (10/20/50/100 μM)
to L929sAhFas cell lysates or MEF cell lysates and incubating with Streptavidin
Sepharose High Performance (GE Healthcare, 17-5113-01). Beads were blocked
with 0.5% BSA (150 mM NaCl, 10 mM Tris-HCl pH 8, 10% glycerol, 0.5% BSA)
before use. After incubation with cell lysates, streptavidin beads were washed with
ice-cold NP-40 lysis buffer (150 mM NaCl, 10 mM Tris-HCl pH 8, 10% glycerol, 1%
NP-40) and eluted by directly adding 2x Laemli buffer. Samples were boiled and
analyzed by immunoblotting (antibodies used as indicated).
Cell death analysis. Cell death was analyzed using a BD Pathway 855 high-
content screening instrument (BD Biosciences) (first screening, Figure 1a).73 Ten
thousand cells were seeded in a black-clear 96-well plate. The next day, the cells
were pretreated with the indicated compounds for 1 h and then stimulated with
mTNF, hTNF or agonistic anti-Fas Ab (concentration as indicated) in the presence of
3 μM propidium iodide (Sigma-Aldrich) and 1 μM Hoechst (Sigma-Aldrich). Images
of at least 1000 cells were taken using a 10x objective and acquired data were
analyzed using the Columbus software package. The percentage PI-positive nuclei
was determined as a measure for cell death. For the second screening shown in
Figure 1b, cell death was measured by incubating dying cells with Cell Titer Glo
reagent (Promega, G7571) for 20 min, followed by analysis using a luminometer
according to the manufacturer’s protocol. All data on L929sAhFas and MEF cells
were analyzed using the BD Pathway imager.
Systemic inflammatory response syndrome. All in vivo experiments
were conducted according to institutional, national and European regulations.
Animal protocols were approved by the ethics committee of Ghent University (SIRS
model). Female C57BL/6 J mice (7–8 weeks old) were purchased from Janvier
(Le Genest, France) for all SIRS experiments. To study the effect of Sorafenib on
TNF-induced SIRS in mice, mice were challenged with 10 μg mTNF (500 mg/kg) in
the presence or absence of Sorafenib. Nec-1s served as a positive control, since it
was shown to protect against TNF-induced SIRS.42,74 Nec-1s (125 μg; 6.25 mg/kg)
was injected intravenously (i.v.) 15 min before mTNF-α challenge, whereas
Sorafenib (10, 50 or 100 mg/kg) or vehicle was given by gavage 1,5 h before
mTNF-α challenge. mTNF-α (10 μg) was injected intravenously (i.v.). Nec-1s
(100 mM stock in DMSO) and mTNF-α were diluted in endotoxin-free PBS and
injected in a volume of 200 μl, while Sorafenib was dissolved in an aqueous solution
containing 8.75% ethanol and 12.5% Chremophor EL (as described earlier in
Sonntag et al.75) and administrated in a total volume of 200 μl. Rectal body
temperature was recorded with an electric thermometer. Plasma samples were
collected and cytokine (mTNF-α and mIL-6) concentrations were determined using
a ProcartaPlex Multiplex Immunoassay (affymetrix, eBioscience) for Luminex200,
according to manufacturer’s protocol. Two samples reached the maximum detection
limit of Luminex and were given 30 000 pg/ml as concentration.
Induction of renal ischemia–reperfusion injury. All in vivo experi-
ments were conducted according to the protocols approved by the Protection of
Animals Act (kidney IRI model). For all IRI experiments, 8-week-old male C57BL/6N
mice (Charles River, Sulzfeld, Germany) were used 15 min before the onset of
ischemia, mice received Sorafenib or vehicle in given concentrations in a total
volume of 200 μl via intraperitoneal injection. Following inhalative induction narcosis
with isoflurane, kidney IRI was performed as described previously.44 See also
Supplementary Materials and Methods.
Statistics. Two or three independent experiments were performed (as indicated
in figure legends) and data were analyzed using GraphPad Prism 6. Values
represent the mean values± standard error of the mean, unless indicated
otherwise. For survival curve analysis, a Log-rank (Mantel-Cox) test was performed.
One-way ANOVA and a Bonferroni multiple comparison test was performed where
indicated. Statistical significance was accepted at Po0.05.
FACS, quantitative PCR, clonogenic assay, synthesis biotinylated Sorafenib. See
Supplementary Material and Methods.
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